|
1
|
El-Serag HB and Mason AC: Rising incidence
of hepatocellular carcinoma in the United States. N Engl J Med.
340:745–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sherman M: Hepatocellular carcinoma:
Epidemiology, risk factors, and screening. Semin Liver Dis.
25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Perz JF, Armstrong GL, Farrington LA,
Hutin YJ and Bell BP: The contributions of hepatitis B virus and
hepatitis C virus infections to cirrhosis and primary liver cancer
worldwide. J Hepatol. 45:529–538. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takayama T, Makuuchi M, Hirohashi S,
Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K
and Yamasaki S: Early hepatocellular carcinoma as an entity with a
high rate of surgical cure. Hepatology. 28:1241–1246. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nagasue N, Uchida M, Makino Y, Takemoto Y,
Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T and Yukaya H:
Incidence and factors associated with intrahepatic recurrence
following resection of hepatocellular carcinoma. Gastroenterology.
105:488–494. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liver Cancer Study Group of Japan: Primary
liver cancer in Japan. Clinicopathologic features and results of
surgical treatment. Ann Surg. 211:277–287. 1990.PubMed/NCBI
|
|
8
|
Jonas S, Bechstein WO, Steinmüller T,
Herrmann M, Radke C, Berg T, Settmacher U and Neuhaus P: Vascular
invasion and histopathologic grading determine outcome after liver
transplantation for hepatocellular carcinoma in cirrhosis.
Hepatology. 33:1080–1086. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pawarode A, Voravud N, Sriuranpong V,
Kullavanijaya P and Patt YZ: Natural history of untreated primary
hepatocellular carcinoma: A retrospective study of 157 patients. Am
J Clin Oncol. 21:386–391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Llovet JM, Bustamante J, Castells A,
Vilana R, Ayuso Mdel C, Sala M, Brú C, Rodés J and Bruix J: Natural
history of untreated nonsurgical hepatocellular carcinoma:
Rationale for the design and evaluation of therapeutic trials.
Hepatology. 29:62–67. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furuse J, Ishii H, Nakachi K, Suzuki E,
Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese
patients with hepatocellular carcinoma. Cancer Sci. 99:159–165.
2008.PubMed/NCBI
|
|
12
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Sakata K, Matsugaki S, Kajiwara M, Fukuizumi K, Tajiri N,
Matsukuma N, et al: Efficacy, safety, and survival factors for
sorafenib treatment in Japanese patients with advanced
hepatocellular carcinoma. Oncology. 84:108–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, et
al: Sorafenib for the treatment of advanced hepatocellular
carcinoma with extrahepatic metastasis: A prospective multicenter
cohort study. Cancer Med. 4:1836–1843. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ando E, Yamashita F, Tanaka M and Tanikawa
K: A novel chemotherapy for advanced hepatocellular carcinoma with
tumor thrombosis of the main trunk of the portal vein. Cancer.
79:1890–1896. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ando E, Tanaka M, Yamashita F, Kuromatsu
R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M:
Hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma with portal vein tumor thrombosis: Analysis of 48 cases.
Cancer. 95:588–595. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chung YH, Song IH, Song BC, Lee GC, Koh
MS, Yoon HK, Lee YS, Sung KB and Suh DJ: Combined therapy
consisting of intraarterial cisplatin infusion and systemic
interferon-alpha for hepatocellular carcinoma patients with major
portal vein thrombosis or distant metastasis. Cancer. 88:1986–1991.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Obi S, Yoshida H, Toune R, Unuma T, Kanda
M, Sato S, Tateishi R, Teratani T, Shiina S and Omata M:
Combination therapy of intraarterial 5-fluorouracil and systemic
interferon-alpha for advanced hepatocellular carcinoma with portal
venous invasion. Cancer. 106:1990–1997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW,
Lee DY, Chon CY, Moon YM and Han KH: Repetitive short-course
hepatic arterial infusion chemotherapy with high-dose
5-fluorouracil and cisplatin in patients with advanced
hepatocellular carcinoma. Cancer. 110:129–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamasaki T, Kimura T, Kurokawa F, Aoyama
K, Ishikawa T, Tajima K, Yokoyama Y, Takami T, Omori K, Kawaguchi
K, et al: Prognostic factors in patients with advanced
hepatocellular carcinoma receiving hepatic arterial infusion
chemotherapy. J Gastroenterol. 40:70–78. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Niizeki T, Sumie S, Torimura T, Kurogi J,
Kuromatsu R, Iwamoto H, Aino H, Nakano M, Kawaguchi A, Kakuma T and
Sata M: Serum vascular endothelial growth factor as a predictor of
response and survival in patients with advanced hepatocellular
carcinoma undergoing hepatic arterial infusion chemotherapy. J
Gastroenterol. 47:686–695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nagamatsu H, Hiraki M, Mizukami N, Yoshida
H, Iwamoto H, Sumie S, Torimura T and Sata M: Intra-arterial
therapy with cisplatin suspension in lipiodol and 5-fluorouracil
for hepatocellular carcinoma with portal vein tumour thrombosis.
Aliment Pharmacol Ther. 32:543–550. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bruix J, Raoul JL, Sherman M, Mazzaferro
V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M,
Sangiovanni A, et al: Efficacy and safety of sorafenib in patients
with advanced hepatocellular carcinoma: Subanalyses of a phase III
trial. J Hepatol. 57:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J: EASL Panel of Experts on HCC: Clinical management of
hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL
conference. European Association for the Study of the Liver. J
Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Forner A, Reig ME, de Lope CR and Bruix J:
Current strategy for staging and treatment: The BCLC update and
future prospects. Semin Liver Dis. 30:61–74. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nakashima T, Okuda K, Kojiro M, Jimi A,
Yamaguchi R, Sakamoto K and Ikari T: Pathology of hepatocellular
carcinoma in Japan. 232 Consecutive cases autopsied in ten years.
Cancer. 51:863–877. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song DS, Bae SH, Song MJ, Lee SW, Kim HY,
Lee YJ, Oh JS, Chun HJ, Lee HG, Choi JY and Yoon SK: Hepatic
arterial infusion chemotherapy in hepatocellular carcinoma with
portal vein tumor thrombosis. World J Gastroenterol. 19:4679–4688.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park KW, Park JW, Choi JI, Kim TH, Kim SH,
Park HS, Lee WJ, Park SJ, Hong EK and Kim CM: Survival analysis of
904 patients with hepatocellular carcinoma in a hepatitis B
virus-endemic area. J Gastroenterol Hepatol. 23:467–473. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okuda K, Ohtsuki T, Obata H, Tomimatsu M,
Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K: Natural history of
hepatocellular carcinoma and prognosis in relation to treatment.
Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Villa E, Moles A, Ferretti I, Buttafoco P,
Grottola A, Del Buono M, De Santis M and Manenti F: Natural history
of inoperable hepatocellular carcinoma: Estrogen receptors' status
in the tumor is the strongest prognostic factor for survival.
Hepatology. 32:233–238. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin CC, Hung CF, Chen WT and Lin SM:
Hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma with portal vein thrombosis: Impact of early response to
4 weeks of treatment. Liver Cancer. 4:228–240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu
H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T,
et al: Alternative treatments in advanced hepatocellular carcinoma
patients with progressive disease after sorafenib treatment: A
prospective multicenter cohort study. Oncotarget. 7:64400–64409.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Paquet KJ, Kalk JF, Cuan-Orozco F, Siemens
F, Koussouris P and Mercado MA: Hepatic chemoinfusion of 5-FU in
metastasis of gastrointestinal cancer and advanced primary
hepatocellular carcinoma. Eur J Surg Oncol. 18:156–161.
1992.PubMed/NCBI
|
|
40
|
Hata F, Sasaki K, Hirata K, Yamamitsu S
and Shirasaka T: Efficacy of a continuous venous infusion of
fluorouracil and daily divided dose cisplatin as adjuvant therapy
in resectable colorectal cancer: A prospective randomized trial.
Surg Today. 38:623–632. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Okabe H, Toko T, Saito H, Nakano K,
Fujioka A, Yuasa C, Takeda S and Unemi N: Augmentation of the
chemotherapeutic effectiveness of UFT, a combination of tegafur
[1-(2-tetrahydrofuryl)-5-fluorouracil] with uracil, by oral
l-leucovorin. Anticancer Res. 17:157–164. 1997.PubMed/NCBI
|
|
42
|
Terayama N, Matsui O, Gabata T, Kobayashi
S, Sanada J, Ueda K, Kadoya M and Kawamori Y: Accumulation of
iodized oil within the nonneoplastic liver adjacent to
hepatocellular carcinoma via the drainage routes of the tumor after
transcatheter arterial embolization. Cardiovasc Intervent Radiol.
24:383–387. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Iavarone M, Cabibbo G, Piscaglia F,
Zavaglia C, Grieco A, Villa E, Cammà C and Colombo M: SOFIA
(SOraFenib Italian Assessment) study group: Field-practice study of
sorafenib therapy for hepatocellular carcinoma: A prospective
multicenter study in Italy. Hepatology. 54:2055–2063. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Breedis C and Young G: The blood supply of
neoplasms in the liver. Am J Pathol. 30:969–977. 1954.PubMed/NCBI
|
|
45
|
Itamoto T, Nakahara H, Tashiro H, Haruta
N, Asahara T, Naito A and Ito K: Hepatic arterial infusion of
5-fluorouracil and cisplatin for unresectable or recurrent
hepatocellular carcinoma with tumor thrombus of the portal vein. J
Surg Oncol. 80:143–148. 2002. View Article : Google Scholar : PubMed/NCBI
|
